Compare Pfizer with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs DIVIS LABORATORIES - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER DIVIS LABORATORIES PFIZER/
DIVIS LABORATORIES
 
P/E (TTM) x 33.4 32.6 102.5% View Chart
P/BV x 5.6 7.4 76.2% View Chart
Dividend Yield % 0.6 0.6 99.7%  

Financials

 PFIZER   DIVIS LABORATORIES
EQUITY SHARE DATA
    PFIZER
Mar-18
DIVIS LABORATORIES
Mar-18
PFIZER/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,3651,142 207.1%   
Low Rs1,625533 304.8%   
Sales per share (Unadj.) Rs430.3146.6 293.5%  
Earnings per share (Unadj.) Rs78.733.0 238.2%  
Cash flow per share (Unadj.) Rs93.238.4 242.6%  
Dividends per share (Unadj.) Rs20.0010.00 200.0%  
Dividend yield (eoy) %1.01.2 84.0%  
Book value per share (Unadj.) Rs586.5222.8 263.2%  
Shares outstanding (eoy) m45.75265.47 17.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.65.7 81.2%   
Avg P/E ratio x25.325.3 100.0%  
P/CF ratio (eoy) x21.421.8 98.2%  
Price / Book Value ratio x3.43.8 90.5%  
Dividend payout %25.430.3 84.0%   
Avg Mkt Cap Rs m91,271222,318 41.1%   
No. of employees `0002.610.8 24.4%   
Total wages/salary Rs m3,1434,561 68.9%   
Avg. sales/employee Rs Th7,484.83,616.0 207.0%   
Avg. wages/employee Rs Th1,195.0423.8 282.0%   
Avg. net profit/employee Rs Th1,369.1814.9 168.0%   
INCOME DATA
Net Sales Rs m19,68538,915 50.6%  
Other income Rs m1,1431,134 100.7%   
Total revenues Rs m20,82840,049 52.0%   
Gross profit Rs m5,00312,617 39.7%  
Depreciation Rs m6631,425 46.5%   
Interest Rs m413 31.6%   
Profit before tax Rs m5,47912,313 44.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8783,543 53.0%   
Profit after tax Rs m3,6018,770 41.1%  
Gross profit margin %25.432.4 78.4%  
Effective tax rate %34.328.8 119.1%   
Net profit margin %18.322.5 81.2%  
BALANCE SHEET DATA
Current assets Rs m24,16745,351 53.3%   
Current liabilities Rs m9,5446,507 146.7%   
Net working cap to sales %74.399.8 74.4%  
Current ratio x2.57.0 36.3%  
Inventory Days Days55127 43.5%  
Debtors Days Days2995 30.2%  
Net fixed assets Rs m9,51421,160 45.0%   
Share capital Rs m458531 86.2%   
"Free" reserves Rs m26,37558,625 45.0%   
Net worth Rs m26,83259,156 45.4%   
Long term debt Rs m250-   
Total assets Rs m36,90067,832 54.4%  
Interest coverage x1,305.5926.8 140.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 93.0%   
Return on assets %9.812.9 75.4%  
Return on equity %13.414.8 90.5%  
Return on capital %20.420.8 98.0%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m2232,359 0.1%   
Fx outflow Rs m1,4899,042 16.5%   
Net fx Rs m-1,46623,317 -6.3%   
CASH FLOW
From Operations Rs m3,3187,759 42.8%  
From Investments Rs m-2,383-4,783 49.8%  
From Financial Activity Rs m-1,104-3,142 35.1%  
Net Cashflow Rs m-169-166 101.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 4.9 19.0 25.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.2 137.8%  
Shareholders   85,207 31,796 268.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  BIOCON   UNICHEM LAB  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 20, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS